Diatrizoate

Diatrizoate
Clinical data
Trade names	Hypaque, Gastrografin, Iothalmate, others
Other names	amidotrizoic acid, diatrizoic acid, 3,5-diacetamido-2,4,6-triiodobenzoic acid
AHFS/Drugs.com	Micromedex Detailed Consumer Information
ATC code	V08AA01 (WHO) ;
Identifiers
	IUPAC name 3,5-Bis(acetylamino)-2,4,6-triiodobenzoic acid;
CAS Number	737-31-5;
PubChem CID	2140;
DrugBank	DB00271;
ChemSpider	2055;
UNII	5UVC90J1LK; V5403H8VG7;
KEGG	D02240;
ChEBI	CHEBI:53691;
ChEMBL	ChEMBL1201220;
CompTox Dashboard (EPA)	DTXSID0044521 ;
ECHA InfoCard	100.003.840
Chemical and physical data
Formula	C11H9I3N2O4
Molar mass	613.916 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I;
	InChI InChI=1S/C11H9I3N2O4/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18/h1-2H3,(H,15,17)(H,16,18)(H,19,20); Key:YVPYQUNUQOZFHG-UHFFFAOYSA-N;

Diatrizoate, also known as amidotrizoate, Gastrografin, is a contrast agent used during X-ray imaging. This includes visualizing veins, the urinary system, spleen, and joints, as well as computer tomography (CT scan). It is given by mouth, injection into a vein, injection into the bladder, through a nasogastric tube, or rectally.

Relatively common side effects include vomiting, diarrhea, and skin redness. Other side effects include itchiness, kidney problems, low blood pressure, and allergic reactions. It is not recommended in people who have an iodine allergy. Diatrizoate is an iodinated ionic radiocontrast agent with high osmolality.

Diatrizoate was approved for medical use in the United States in 1954. It is on the World Health Organization's List of Essential Medicines.